Raredr

US Military Members Diagnosed with Keratoconus Become First Patients Treated with Ophthalmic Therapy

Andrew Black
Published Online: Wednesday, Jan 11, 2017
Military Service Members diagnosed with keratoconus located in the Fort Belvoir Hospital, located in Virginia became the first patients treated with the only FDA approved corneal cross-linking procedure. Keratoconus previously had no surgical treatment available. 
 
Before Avedro’s cross-linking treatment procedure, keratoconus patients were forced to wear specialized contact lenses. This caused major issues for those serving in the military because contact lenses aren’t approved for combat. With the new treatment procedure, this is no longer a problem.
 
The corneal collagen cross-linking is designed with Avedro’s Photrexa Viscous, Photrexa and the KXL system. Photrexa Viscous, Photrexa are photoenhancers indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.
 
Avedro’s corneal cross-linking procedure was approved in April 2016.

About keratoconus

Keratoconus is a rare condition in which the cornea thins and gradually bulges outward into a cone shape.
 
Corneal ectasia is a rare outcome of lasik or photorefractive keratectomy surgery. It can begin within a week of surgery or after several years and is associated with worsening best-uncorrected visual acuity, an increase in ocular aberrations, and decreasing best-corrected distance visual acuity. It can lead to vision loss.

To stay informed on the latest in rare disease news and developments, please sign up for our weekly newsletter at www.raredr.com/newsletter


Latest Articles
The FDA Advisory Committee voted 10-to-3 in favor of approving Endari (L-glutamine) for sickle cell disease.
Nabila Bouatia-Naji, PhD of INSERM talks about the genetics of fibromuscular dysplasia (FMD) and the studies she is involved with to better understand this rare condition.
The small girl who got pulled into the harbor by a sea lion this week may have seal finger, a rare infection resulting from the encounter.
A new study by Hughes et al indicates long-term use of Vimizim (elosulfase afla) in adults with Morquio A is effective and provides those patients with increased strength and endurance to tackle their daily activities.
$vacMongoViewPlus$ $vAR$